Exploring the interactions of Irbesartan (cas 138402-11-6) and Irbesartan (cas 138402-11-6)–2-hydroxypropyl-β-cyclodextrin complex with model membranes
-
Add time:08/29/2019 Source:sciencedirect.com
The interactions of Irbesartan (cas 138402-11-6) (IRB) and irbesartan–2-hydroxypropyl-β-cyclodextrin (HP-β-CD) complex with dipalmitoyl phosphatidylcholine (DPPC) bilayers have been explored utilizing an array of biophysical techniques ranging from differential scanning calorimetry (DSC), small angle X-ray scattering (SAXS), ESI mass spectrometry (ESI-MS) and solid state nuclear magnetic resonance (ssNMR). Molecular dynamics (MD) calculations have been also conducted to complement the experimental results. Irbesartan was found to be embedded in the lipid membrane core and to affect the phase transition properties of the DPPC bilayers. SAXS studies revealed that irbesartan alone does not display perfect solvation since some coexisting irbesartan crystallites are present. In its complexed form IRB gets fully solvated in the membranes showing that encapsulation of IRB in HP-β-CD may have beneficial effects in the ADME properties of this drug. MD experiments revealed the topological and orientational integration of irbesartan into the phospholipid bilayer being placed at about 1 nm from the membrane centre.
We also recommend Trading Suppliers and Manufacturers of Irbesartan (cas 138402-11-6). Pls Click Website Link as below: cas 138402-11-6 suppliers
Prev:Original ArticleTargeting the proinflammatory cytokines, oxidative stress, apoptosis and TGF-β1/STAT-3 signaling by Irbesartan (cas 138402-11-6) to ameliorate doxorubicin-induced hepatotoxicity☆
Next:Irbesartan (cas 138402-11-6) attenuates advanced glycation end products-mediated damage in diabetes-associated osteoporosis through the AGEs/RAGE pathway) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Renal protective effect of SGLT2 inhibitor dapagliflozin alone and in combination with Irbesartan (cas 138402-11-6) in a rat model of diabetic nephropathy09/01/2019
- Original ArticleChronomodulated drug delivery system of Irbesartan (cas 138402-11-6): Formulation and development using Desing of Experiment (DoE)08/31/2019
- Irbesartan (cas 138402-11-6) attenuates advanced glycation end products-mediated damage in diabetes-associated osteoporosis through the AGEs/RAGE pathway08/30/2019
- Original ArticleTargeting the proinflammatory cytokines, oxidative stress, apoptosis and TGF-β1/STAT-3 signaling by Irbesartan (cas 138402-11-6) to ameliorate doxorubicin-induced hepatotoxicity☆08/28/2019
- The thermal decomposition mechanism of Irbesartan (cas 138402-11-6)08/27/2019
- Immunopharmacology and inflammationSuppressive effects of type I angiotensin receptor antagonists, candesartan and Irbesartan (cas 138402-11-6) on allergic asthma08/26/2019
- Irbesartan (cas 138402-11-6) desmotropes: Solid-state characterization, thermodynamic study and dissolution properties08/25/2019
- Downstream processing of Irbesartan (cas 138402-11-6) nanocrystalline suspension and mini-tablet development – Part II08/24/2019
- ReviewShould we add atorvastatin to Irbesartan (cas 138402-11-6) for improving renoprotective effects in early diabetic nephropathy? A meta-analysis of randomized controlled trials08/23/2019
-
Health and Chemical more >
-
Related Products